Developer docs
API playgroundTry for free, no card

Search company profiles

Yuhan USA

Full company profile

uuid003446o

Namestring
Yuhan USA
Legal namestring
Yuhan USA Corporation
Websiteurl
yuhan-usa.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Yuhan USA Corporation is a Cambridge, Massachusetts-based subsidiary of the South Korean pharmaceutical company Yuhan Corporation (KOSPI: 000100), operating as the parent group's US market entry and commercialization arm. Founded in 2018 and staffed at 1-10 employees, it provides local US infrastructure — sales channel development, localized marketing, FDA regulatory approval support, and logistics operations — for partner healthcare products seeking to enter the US market.

The subsidiary's portfolio centers on two pillars. In pharmaceuticals, it supports US commercialization of parent-pipeline assets such as Leclaza, a lung cancer therapy that received FDA approval in August 2024. In digital health, it executed a strategic partnership with Huinno in March 2026 to bring AI-based cardiac monitoring products (MEMO Patch M, MEMO Cue, MEMO Care) and the Vital-PICASO clinical prediction platform into US hospital and provider channels. Underlying technology at the parent level includes AI-based drug development platforms and next-generation targeted protein degradation (TPD) technology aimed at first-in-class candidates.

Revenue mechanics rely on pharmaceutical product commercialization (including royalties/licenses from partnered drugs) plus partnership-driven fee or margin contributions from digital health distribution. Yuhan Corporation's roughly 250 billion won annual R&D outlay and its pivot toward NewCo/co-development structures with global pharma partners suggest upstream pipeline scaling, while Yuhan USA absorbs the US commercialization workload. Customer base is concentrated in healthcare providers and patients, with global pharma companies as a secondary partner segment.

Short descriptiontext

Yuhan USA Corporation is the US commercialization arm of Korean pharma Yuhan Corporation, providing regulatory, sales, marketing, and logistics support to bring partner pharmaceutical and digital health products — including lung cancer therapy Leclaza and AI-based cardiac monitoring devices — into the US healthcare market.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
pharmaceutical commercialization, drug development partnerships, US market entry services, cardiac monitoring solutions, regulatory approval support
Industry2 codes
PRIMARYHLAIAJAC
OTC & Consumer Health Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYBPADANAJ
Health, Pharmaceuticals & Medical Devices Regulatory Cooperation
Business & Public Services/International Organizations & Development/International Standards, Policy & Regulatory Cooperation
NAICS code2 codes
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Pharmaceutical Commercialization Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical drug development and sales
TypeLicensing Royalties
Description

Yuhan generates revenue through development and commercialization of pharmaceutical products, including lung cancer therapy Leclaza approved by FDA in August 2024. The company is pivoting to co-development and NewCo entity structures to share risk and revenue with global pharmaceutical partners for late-stage clinical trials.

biz.chosun.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Marketing or Sales, Operations, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Yuhan USA is the US commercialization arm of Yuhan Corporation, providing sales channel development, localized marketing, regulatory approval support, and logistics operations for partner pharmaceutical and digital health products entering the US healthcare market. The company supports co-development arrangements and licenses pharmaceutical innovations such as FDA-approved lung cancer therapy Leclaza for the US market.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Lung cancer therapy Leclaza received FDA approval in August 2024
+1 more record
Product overview1 text field

Yuhan USA serves as the US commercialization arm for both pharmaceutical and digital health products. In pharmaceuticals, the flagship product is Leclaza (FDA-approved August 2024 for lung cancer), representing Yuhan's breakthrough in the US market. In digital health, Yuhan USA partners with Huinno to commercialize AI-driven cardiac monitoring solutions including MEMO Patch M, MEMO Cue, MEMO Care, and the Vital-PICASO clinical prediction platform, leveraging Yuhan USA's local sales channels, marketing, regulatory approval support, and logistics capabilities.

Product and service6 records
1Leclaza (Lazcluze)
CategoryPharmaceutical Product
2US Commercialization Services
CategoryCommercialization Services
3MEMO Patch M
CategoryDigital Health Product
4MEMO Cue
CategoryDigital Health Product
5MEMO Care
CategoryDigital Health Product
6Vital-PICASO
CategoryClinical Prediction Platform
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-30
Description

Huinno, an AI-based cardiac monitoring startup, has partnered with Yuhan USA Corporation to expand its ECG monitoring solutions into the US digital healthcare market. The partnership covers sales channel development, localized marketing, regulatory approval support, and logistics operations for Huinno's product lineup including MEMO Patch M, MEMO Cue, MEMO Care, and the clinical prediction platform Vital-PICASO. The collaboration combines Huinno's AI-driven monitoring technologies with Yuhan USA's local commercialization capabilities to accelerate adoption within the US healthcare system.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

India-based multinational with a substantial US pharmaceutical generics and specialty business. Broad incumbent peer on international-to-US pharma commercialization at scale.

2Sun Pharmaceutical Industries
TypeBroad incumbent
Description

India-headquartered global pharma with a sizable US subsidiary commercializing a broad specialty and generics portfolio. Comparable as a large international pharma with US commercialization infrastructure and partnership activity.

TypeEmerging player
Description

US-based digital cardiac monitoring company (e.g., Zio patch) — directly analogous to the Huinno MEMO Patch / ECG solutions Yuhan USA is commercializing. Relevant peer for the digital-health portion of Yuhan USA's portfolio.

TypeRegional player
Description

Korean pharmaceutical company with US commercialization ambitions and licensed products in the US. Comparable as another Korea-rooted company pursuing US pharmaceutical distribution and partnerships.

TypeDirect peer
Description

Korean biopharmaceutical company with a US subsidiary commercializing biosimilars across regulatory, distribution and sales channels. Highly comparable as a Korea-headquartered firm scaling into US pharmaceutical markets.

TypeBroad incumbent
Description

International pharmaceutical company with a large US specialty/generics distribution business. Broader peer for US pharmaceutical distribution scale, channel relationships, and institutional customer access.

TypeDirect peer
Description

Korean pharmaceutical company with US presence focused on bringing parent-company products to the US market via local commercialization and partnership deals — closely comparable model to Yuhan USA.

TypeDirect peer
Description

Korean pharmaceutical company with active US commercialization subsidiary. Direct peer on cross-border pharma commercialization: a Korean parent with established US distribution/partnerships model for prescription and specialty drugs.

9Chong Kun Dang Pharmaceutical
TypeRegional player
Description

Korean pharmaceutical manufacturer with selective US market entry efforts. Comparable regional Korean-pharma peer building US-side distribution and partnership capabilities.

10LG Chem Life Sciences
TypeDirect peer
Description

Korean life sciences business pursuing US market entry for parent-developed innovative drugs, including partnerships and co-development models — comparable in the cross-border pharma commercialization structure.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Yuhan USA

Pharmaceutical Commercialization Servicesyuhan-usa.com

Yuhan USA Corporation is the US commercialization arm of Korean pharma Yuhan Corporation, providing regulatory, sales, marketing, and logistics support to bring partner pharmaceutical and digital health products — including lung cancer therapy Leclaza and AI-based cardiac monitoring devices — into the US healthcare market.

What Yuhan USA does

Yuhan USA Corporation is a Cambridge, Massachusetts-based subsidiary of the South Korean pharmaceutical company Yuhan Corporation (KOSPI: 000100), operating as the parent group's US market entry and commercialization arm. Founded in 2018 and staffed at 1-10 employees, it provides local US infrastructure — sales channel development, localized marketing, FDA regulatory approval support, and logistics operations — for partner healthcare products seeking to enter the US market.

The subsidiary's portfolio centers on two pillars. In pharmaceuticals, it supports US commercialization of parent-pipeline assets such as Leclaza, a lung cancer therapy that received FDA approval in August 2024. In digital health, it executed a strategic partnership with Huinno in March 2026 to bring AI-based cardiac monitoring products (MEMO Patch M, MEMO Cue, MEMO Care) and the Vital-PICASO clinical prediction platform into US hospital and provider channels. Underlying technology at the parent level includes AI-based drug development platforms and next-generation targeted protein degradation (TPD) technology aimed at first-in-class candidates.

Revenue mechanics rely on pharmaceutical product commercialization (including royalties/licenses from partnered drugs) plus partnership-driven fee or margin contributions from digital health distribution. Yuhan Corporation's roughly 250 billion won annual R&D outlay and its pivot toward NewCo/co-development structures with global pharma partners suggest upstream pipeline scaling, while Yuhan USA absorbs the US commercialization workload. Customer base is concentrated in healthcare providers and patients, with global pharma companies as a secondary partner segment.

Yuhan USA firmographics

Firmographics
Name
Yuhan USA
Legal name
Yuhan USA Corporation
Website
https://yuhan-usa.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Yuhan USA Corporation is the US commercialization arm of Korean pharma Yuhan Corporation, providing regulatory, sales, marketing, and logistics support to bring partner pharmaceutical and digital health products — including lung cancer therapy Leclaza and AI-based cardiac monitoring devices — into the US healthcare market.
Ownership category
akta.pro rank

Yuhan USA industry classification

Industry
Product category
Pharmaceutical Commercialization Services
NAICS
Drugs and Druggists' Sundries Merchant Wholesalers (42421), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAJAC
OTC & Consumer Health Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
SECONDARYBPADANAJ
Health, Pharmaceuticals & Medical Devices Regulatory Cooperation
Business & Public Services/International Organizations & Development/International Standards, Policy & Regulatory Cooperation

Keywords

  • Pharmaceutical commercialization
  • Drug development partnerships
  • US market entry services
  • Cardiac monitoring solutions
  • Regulatory approval support

Where Yuhan USA is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Markets served

Yuhan USA business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Marketing or Sales, Operations, Technology or R&D

Revenue model

  1. Pharmaceutical drug development and sales: Yuhan generates revenue through development and commercialization of pharmaceutical products, including lung cancer therapy Leclaza approved by FDA in August 2024. The company is pivoting to co-development and NewCo entity structures to share risk and revenue with global pharmaceutical partners for late-stage clinical trials.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Yuhan USA product offering

Product offering

Core offering

Yuhan USA is the US commercialization arm of Yuhan Corporation, providing sales channel development, localized marketing, regulatory approval support, and logistics operations for partner pharmaceutical and digital health products entering the US healthcare market. The company supports co-development arrangements and licenses pharmaceutical innovations such as FDA-approved lung cancer therapy Leclaza for the US market.

Product overview

Yuhan USA serves as the US commercialization arm for both pharmaceutical and digital health products. In pharmaceuticals, the flagship product is Leclaza (FDA-approved August 2024 for lung cancer), representing Yuhan's breakthrough in the US market. In digital health, Yuhan USA partners with Huinno to commercialize AI-driven cardiac monitoring solutions including MEMO Patch M, MEMO Cue, MEMO Care, and the Vital-PICASO clinical prediction platform, leveraging Yuhan USA's local sales channels, marketing, regulatory approval support, and logistics capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

  • Leclaza (Lazcluze)
  • US Commercialization Services
  • MEMO Patch M
  • MEMO Cue
  • MEMO Care
  • Vital-PICASO

Quantifiable outcome

  • Lung cancer therapy Leclaza received FDA approval in August 2024
  • +1 more outcomes

Companies that use Yuhan USA

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Yuhan USA technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Yuhan USA partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • HuinnocoreStrategic or Co-development Partner · 30 March 2026Huinno, an AI-based cardiac monitoring startup, has partnered with Yuhan USA Corporation to expand its ECG monitoring solutions into the US digital healthcare market. The partnership covers sales channel development, localized marketing, regulatory approval support, and logistics operations for Huinno's product lineup including MEMO Patch M, MEMO Cue, MEMO Care, and the clinical prediction platform Vital-PICASO. The collaboration combines Huinno's AI-driven monitoring technologies with Yuhan USA's local commercialization capabilities to accelerate adoption within the US healthcare system.

Scale indicators3 records

Recent moves4 records

Expansion highlights5 records

Yuhan USA competitors and assessment

Company assessment

Broad incumbents

  • Dr. Reddy's Laboratories: India-based multinational with a substantial US pharmaceutical generics and specialty business. Broad incumbent peer on international-to-US pharma commercialization at scale.
  • Sun Pharmaceutical Industries: India-headquartered global pharma with a sizable US subsidiary commercializing a broad specialty and generics portfolio. Comparable as a large international pharma with US commercialization infrastructure and partnership activity.
  • Hikma Pharmaceuticals: International pharmaceutical company with a large US specialty/generics distribution business. Broader peer for US pharmaceutical distribution scale, channel relationships, and institutional customer access.

Emerging players

  • iRhythm Technologies: US-based digital cardiac monitoring company (e.g., Zio patch) — directly analogous to the Huinno MEMO Patch / ECG solutions Yuhan USA is commercializing. Relevant peer for the digital-health portion of Yuhan USA's portfolio.

Regional players

  • Boryung Pharmaceutical: Korean pharmaceutical company with US commercialization ambitions and licensed products in the US. Comparable as another Korea-rooted company pursuing US pharmaceutical distribution and partnerships.
  • Chong Kun Dang Pharmaceutical: Korean pharmaceutical manufacturer with selective US market entry efforts. Comparable regional Korean-pharma peer building US-side distribution and partnership capabilities.

Direct peers

  • Celltrion: Korean biopharmaceutical company with a US subsidiary commercializing biosimilars across regulatory, distribution and sales channels. Highly comparable as a Korea-headquartered firm scaling into US pharmaceutical markets.
  • Daewoong Pharmaceutical: Korean pharmaceutical company with US presence focused on bringing parent-company products to the US market via local commercialization and partnership deals — closely comparable model to Yuhan USA.
  • Hanmi Pharmaceutical: Korean pharmaceutical company with active US commercialization subsidiary. Direct peer on cross-border pharma commercialization: a Korean parent with established US distribution/partnerships model for prescription and specialty drugs.
  • LG Chem Life Sciences: Korean life sciences business pursuing US market entry for parent-developed innovative drugs, including partnerships and co-development models — comparable in the cross-border pharma commercialization structure.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Yuhan USA social profiles

Digital presence

Yuhan USA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Yuhan USA leadership team

Management profile

Number of profiles

Yuhan USA funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Yuhan USA M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Yuhan USA

What does Yuhan USA do?

Yuhan USA is the US commercialization arm of Yuhan Corporation, providing sales channel development, localized marketing, regulatory approval support, and logistics operations for partner pharmaceutical and digital health products entering the US healthcare market. The company supports co-development arrangements and licenses pharmaceutical innovations such as FDA-approved lung cancer therapy Leclaza for the US market.

Is Yuhan USA a public or private company?

Yuhan USA is a private company. It is classified as corporate owned and is currently operating.

When was Yuhan USA founded?

Yuhan USA was founded in 2018. It employs 11 to 50 people.

Where is Yuhan USA based?

Yuhan USA is headquartered in Cambridge, United States, in the North America region.

How does Yuhan USA make money?

One revenue line is on record: pharmaceutical drug development and sales.

Who are Yuhan USA's main competitors?

Broad incumbents on record are Dr. Reddy's Laboratories, Sun Pharmaceutical Industries and Hikma Pharmaceuticals. iRhythm Technologies is listed as an emerging player. Regional players are Boryung Pharmaceutical and Chong Kun Dang Pharmaceutical. Direct peers are Celltrion, Daewoong Pharmaceutical, Hanmi Pharmaceutical and LG Chem Life Sciences.

Does Yuhan USA have an API?

No public API is recorded for Yuhan USA.

What industry is Yuhan USA in?

Yuhan USA's product category is Pharmaceutical Commercialization Services. Its primary akta.pro industry code is HLAIAJAC, OTC & Consumer Health Distributors, with a secondary code of BPADANAJ, Health, Pharmaceuticals & Medical Devices Regulatory Cooperation. Its NAICS code is 42421 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals